A prospective study of nanofractional radiofrequency (Venus Viva) for the treatment of acne scarring and rhytids in skin types II-IV, published in the Journal of Cosmetic Dermatology (September 24, 2021), found the treatments are safe, comfortable and result in good patient satisfaction.
Suleima Arruda, MD, Alyssa Swearingen, BS, Kathleen Medrano, BS, and Neil Sadick MD, authored the study, which included 30 subjects (skin types II-IV) with facial wrinkles and/or acne scarring. The average age of subjects was 51.9 ± 13.5 years.
Subjects underwent three treatments with the nanofractional RF devices at three- to five-week intervals on both sides of the face using either the 80-pin or 160-pin disposable tip. Outcomes were assessed at six week and 12 week follow-up visits.
The investigators evaluated subject satisfaction using a subject self-assessment of reduction in wrinkles or acne scars, and subject satisfaction questionnaire. Pain, tolerability and safety were monitored throughout the course of treatment.
At the six week and 12-week follow-up visits, subjects were satisfied with their results (mean score 3.0; range 0 = very unsatisfied to 4 = very satisfied). The treatments were well tolerated at all treatment sessions, averaging a score of 3.5 on the tolerability scale (0 = very intolerable to 4 = very tolerable) with treatment-associated pain reported to be mild (3.2 out of 10). The authors reported no adverse events or unanticipated side effects.